Highest risk for testing positive or death due to COVID-19 was seen for non-White essential workers
Hyposmia, Dysgeusia Common for Patients With COVID-19
Total leukocyte and neutrophil counts lower among patients with hyposmia
Drop in ED Visits Related to Child Abuse, Neglect During COVID-19
Decrease in total number of ED visits versus corresponding 2019 period, but proportion of these visits increased
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Dec. 7 to 11, 2020. This …
BNT162b2 Vaccine 95 Percent Effective for Preventing COVID-19
Published data on Pfizer-BioNTech vaccine show similar efficacy across subgroups based on age, race, BMI, presence of coexisting conditions
U.S. Marshals to Protect COVID-19 Vaccines
Deputies will be posted at stockpiles, manufacturers, transport areas, and receiving facilities
ED Visits Related to Child Abuse, Neglect Dropped During COVID-19
Total number of ED visits decreased versus corresponding 2019 period, but proportion of these visits increased
Pennsylvania Developed COVID-19 Vaccine Candidate Expands Study in China
A biotechnology company announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China.
The Phase 2 clinical trial being conducted in China will enroll approximately 640 participants who are 18 years or older.
INOVIO and Advaccine Biopharmaceuticals Suzhou Co., Ltd. announced in a press release on December 10, 2020, the dosing regimen involves two vaccinations at 0 and 28 days, with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of Phase 2/3 clinical trial in the USA.
Ulcerative Colitis Treatment Prepares for Phase 3 Study
A clinical-stage biotechnology company announced the progression of its development program for its lead drug candidate, ABX464, into phase 3 preparation for the treatment of moderate-to-severe ulcerative colitis (UC).